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Abstract Recent findings indicate that cytokine signaling can
be modulated by other mediators of simultaneously activated
signal transduction pathways. In this study we show that LPS
and TNFK are potent inhibitors of IL-6-mediated STAT3
activation in human monocyte derived macrophages, rat liver
macrophages and RAW 264.7 mouse macrophages but not in
human hepatoma cells (HepG2) or in rat hepatocytes. Accord-
ingly, LPS and TNFK were found to induce the expression of
SOCS3 mRNA in each of the investigated type of macrophages
but not in HepG2 cells. Using a specific inhibitor, evidence is
presented that the p38 MAP kinase might be involved, especially
for the inhibitory effect of TNFK.
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1. Introduction
Interleukin-6 is a multifunctional cytokine with pro- as well
as anti-in£ammatory properties (for review, see Ref. [1]). IL-6
regulates its target genes by binding to its respective receptor
complex, thereby activating tyrosine kinases of the Janus (Jak)
family, followed by tyrosine phosphorylation, dimerization
and nuclear translocation of mainly signal transducer and
activator of transcription (STAT)3 (for review, see Ref. [2]).
Recently, it became evident that the Jak/STAT pathway can
be modulated by mediators of other simultaneously activated
signal transduction pathways.
Thus, it has been shown that lipopolysaccharide (LPS)
strongly enhances the interferon (IFN)-Q-induced activation
of STAT1 [3]. On the other hand, activation of the mitogen-
activated protein (MAP) kinases Erk-1 and Erk-2 by ¢bro-
blast growth factor or the phorbol ester PMA inhibits the
IL-6-induced STAT activation ([4], Terstegen/Graeve, unpub-
lished work). Moreover, activation of protein kinase A or
protein kinase C [5^7] as well as stimulation by transforming
growth factor L, granulocyte/macrophage-colony-stimulating
factor or angiotensin II [7^10] inhibits the activation of the
Jak/STAT pathway by various cytokines.
Pre-incubation of monocytes with IL-10 attenuated the ex-
pression of IFNK/L-inducible genes through inhibition of
STAT1 activation. It was further shown that IL-10 induces
the expression of the suppressor of cytokine signaling (SOCS)-
3 [11]. Since binding of SOCS proteins to tyrosine kinases of
the Janus family inhibits downstream activation of STATs
[12] it was suggested that IL-10 inhibits IFN-induced STAT
activation via induction of SOCS3.
In this study we explored the e¡ect of two mediators of
in£ammation, LPS and tumor necrosis factor K (TNFK) on
IL-6 signaling in monocytic and hepatic cells. We found the
IL-6-induced activation of STAT3 to be inhibited by pre-in-
cubation of macrophages with LPS or TNFK. This inhibition
is paralleled by increased SOCS3 mRNA levels. Inhibitor
studies indicate the involvement of the p38 mitogen-activated
protein kinase (MAP kinase), especially for the inhibitory ef-
fect of TNFK.
2. Materials and methods
2.1. Materials
Recombinant human TNFK and LPS were purchased from Boehr-
inger Mannheim (Mannheim, Germany). Oligonucleotides were ob-
tained from MWG Biotech (Ebersberg, Germany), SB 202190 [13]
from Calbiochem (Bad Soden, Germany). RPMI 1640 and L-gluta-
mine were from Biowhittaker (Verviers, Belgium); S-MEM spinner
medium and Dulbecco’s modi¢ed Eagle’s medium (DMEM) from
Life Technologies (Eggenstein, Germany). Fetal calf serum was
from Seromed (Berlin, Germany). Recombinant human IL-6 was pre-
pared as described [14]. Lympho£ot was from Biotest (Dreieich, Ger-
many), Percoll from Sigma (Deisenhofen, Germany) and Nycodenz
from Nycomed (Oslo, Norway).
2.2. Isolation and cultivation of rat liver macrophages
Liver macrophages (KC, Kup¡er cells) were isolated from 1 year
old male Wistar rats by collagenase-pronase perfusion and separated
by a single Nycodenz gradient and centrifugal elutriation [15]. Cells
were cultured in a 60 mm dish in RPMI 1640 medium supplemented
with 10% heat-inactivated fetal calf serum (FCS) and 1% gentamicin
for up to 48 h in a humidi¢ed atmosphere of 5% CO2 and 95% air at
37‡C. Culture medium was changed after 24 h. Purity of KC was
v 97% as assessed 24 h after seeding by their typical light microscopic
appearance, by immunological staining for the speci¢c macrophage
marker protein ED2 [16], and by their ability to phagocytose £uores-
cent 1.1 Wm latex particles.
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2.3. Isolation and cultivation of parenchymal cells from rat liver
Isolated parenchymal cells were prepared from livers of 5^8 weeks
old male Wistar rats by a collagenase perfusion technique as described
[17]. Cells were plated on collagen-coated culture dishes and main-
tained in Krebs-Henseleit medium supplemented with 6 mmol/l glu-
cose. After 2 h medium was removed and the culture was continued
for 24 h in DMEM containing 5% fetal calf serum, 100 mg/l penicillin/
streptomycin, 100 nmol/l insulin, 100 nmol/l dexamethasone, 30 nmol/
l Na-selenite and 1 mg/l aprotinin.
2.4. Isolation and cultivation of macrophages derived from human blood
Human monocytes were isolated from bu¡y coats, kindly provided
by the local blood bank (Transfusionsmedizin, RWTH Aachen, Ger-
many) with a Lympho£ot gradient followed by hypertonic density
centrifugation in Percoll. After 30 min cultivation in RPMI supple-
mented with 5% human serum and 1% L-glutamine the monocytes
became adherent and were washed three times with S-MEM spinner
medium to remove contaminating lymphocytes. Experiments were
performed after 4 days of cultivation. All solutions and materials
contacting monocytes/macrophages were LPS tested by the manufac-
turers or by ourselves with the limulus amoebocyte limusate test
(LAL-Test, Kappes, Laborservice, Augsburg, Germany). Serum
from healthy human volunteers was sterile ¢ltered and heat inacti-
vated. Serum was only used for cell culture when IL-6 and TNFK
were below 11.3 pg/ml and 8.1 pg/ml as measured by Immulite (Bier-
mann, Bad Nauheim, Germany) according to the manufacturer’s in-
structions. Serum from a minimum of four volunteers was pooled.
2.5. Cultivation and stimulation of cells
The murine peritoneal macrophage cell line RAW 264.7 and the
human hepatoma cell line HepG2 were grown in RPMI 1640 or in
DMEM/nut mix F12 medium, respectively, supplemented with 10%
fetal calf serum, streptomycin (100 mg/l) and penicillin (60 mg/l).
Medium was changed and adjusted to 5 ml 24 h before experiments
were carried out.
Cells grown in a 60 mm (KC) or 100 mm (RAW 264.7, MC) dish
were stimulated with LPS, TNFK or IL-6 at the concentrations in-
dicated. SB 202190 was dissolved in dimethyl sulfoxide and added to
the culture medium 40 min before stimulation at concentrations as
indicated in the ¢gure legends. Nuclear extracts were prepared as
described by Andrews and Faller [18]. Protein concentrations were
determined with a Bio-Rad protein assay.
2.6. Electrophoretic mobility shift assay (EMSA)
EMSAs were performed as described previously [19] using a double-
stranded 32P-labeled mutated m67SIE-oligonucleotide from the c-fos
promoter (m67SIE: 5P-GAT CCG GGA GGG ATT TAC GGG
GAA ATG CTG-3P) [20]. The protein-DNA complexes were sepa-
rated on a 4.5% polyacrylamide gel containing 7.5% glycerol in
0.25-fold TBE (20 mM Tris, 20 mM boric acid, 0.5 mM EDTA) at
20 V/cm for 4 h. Gels were ¢xed in 10% methanol, 10% acetic acid
and 80% water for 1 h, dried and autoradiographed.
2.7. Total RNA isolation and Northern blot analysis
Total RNA was isolated using RNeasy mini kit (Qiagen, Hilden,
Germany) as described by the manufacturer. 10 Wg of total RNA were
separated on 1% denaturating agarose gels and transferred to Nitro-
Plus transfer membrane (MSI, Westboro, WI, USA). The membranes
were pre-hybridized at 68‡C for 2 h in 10% dextran sulfate, 1 M
sodium chloride, 1% SDS, and hybridized over night in the same
solution with cDNA fragments labeled with Random Primed DNA
Labeling kit (Boehringer Mannheim GmbH, Germany). Blots were
exposed to Kodak X-OMAT AR-5 ¢lm at 370‡C with intensifying
screens. Suitably exposed autoradiograms were then analyzed by den-
Fig. 1. E¡ect of LPS or TNFK pre-treatment on IL-6 induced STAT3 activation in macrophages. Human macrophages (a,b), rat liver macro-
phages (c,d) and the mouse macrophage cell line RAW 264.7 (e,f) were pre-treated with either LPS or TNFK as indicated and subsequently
stimulated with IL-6. After the respective incubation period cells were harvested and nuclear extracts prepared and analyzed as described in
Section 2. 5 Wg of nuclear extracts were mixed with a 32P-labeled oligonucleotide (mutated SIE probe of the c-fos promoter 5P-GAT CCG
GGA GGG ATT TAC GGG GAA ATG CTG-3P) and EMSAs were performed. The DNA-protein complexes formed were separated from the
free probe by electrophoresis on a native 4.5% gel.
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sitometry scanning (PDI, New York, USA). Glycerin aldehyde-3-
phosphate dehydrogenase (GAPDH) cDNA probe was kindly pro-
vided by Dr. Burchart-Graeve (RWTH Aachen, Germany) and
SOCS3 cDNA probe by Dr. Hilton (The Walter and Eliza Hall In-
stitute of Medial Research, Parkville, Vic., Australia).
3. Results
Recent ¢ndings of several groups indicate that cytokine
signaling can be modulated by other mediators of simultane-
ously activated signal transduction pathways [3^12]. There-
fore, we investigated whether IL-6-induced signaling is in£u-
enced by LPS or TNFK, important pro-in£ammatory
mediators. Pre-incubation of human macrophages isolated
from peripheral blood (Fig. 1a,b), rat liver macrophages
(Fig. 1c,d) or RAW 264.7 murine peritoneal macrophages
(Fig. 1e,f) with either LPS or TNFK dose dependently sup-
pressed IL-6-induced activation of STAT3 as assessed by an
EMSA with an oligonucleotide from the c-fos promoter [20].
Since SOCS3 is known to be a cytokine-inducible suppres-
sor of cytokine signal transduction [12] we asked whether
there is a correlation between inhibition of STAT3 activation
and induction of SOCS3 expression. As shown in Fig. 2 LPS
(Fig. 2a,c, e) as well as TNFK (Fig. 2b,d,f) induced the ex-
pression of SOCS3 mRNA in all three types of macrophages.
Thus, it is possible that inhibition of IL-6 signal transduction
by LPS or TNFK might be due to the de novo synthesis of
SOCS3.
Most interestingly, the inhibition of IL-6-stimulated activa-
tion of STAT3 by LPS or TNFK was not observed in primary
hepatocytes isolated from rat liver (Fig. 3b,d) or the human
hepatoma cell line HepG2 (Fig. 3a,c) even at high concentra-
tions of LPS or TNFK. Likewise, induction of SOCS3 mRNA
by LPS or TNFK was found to depend on the cell type in-
vestigated, since neither TNFK nor LPS were able to induce
SOCS3 mRNA in HepG2 cells (Fig. 3e). These data strongly
suggest that inhibition of IL-6 signaling by LPS or TNFK is a
speci¢c feature of macrophages.
Activation of members of the MAP kinase family has been
shown to have an inhibitory e¡ect on cytokine signaling ([4],
Terstegen/Graeve, unpublished work). Hence, we were inter-
ested to ¢nd out whether MAP kinases are involved in the
inhibition of IL-6-induced STAT3 activation by LPS or
TNFK. As shown in Fig. 4 pre-incubation of RAW 264.7
mouse macrophages with a speci¢c inhibitor of the p38
MAP kinase (SB202190) almost completely blocks the inhib-
ition of STAT3 activation by TNFK (Fig. 4a,b), whereas the
LPS e¡ect was only partially a¡ected (Fig. 4c). Accordingly in
Fig. 2. Induction of the SOCS3 mRNA expression in macrophages by LPS or TNFK. Human macrophages (a,b), rat liver macrophages (c,d)
and RAW 264.7 mouse peritoneal macrophages (e,f) were treated with IL-6, LPS or with TNFK as indicated. After the respective incubation
period cells were harvested for isolation of total RNA and subjected to Northern blot analysis for SOCS3 and GAPDH (loading control) as
described in Section 2.
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RAW 264.7 cells (Fig. 5a) and liver macrophages the TNFK
(Fig. 5b) mediated SOCS3 mRNA expression was reduced to
basic expression levels by the inhibition of p38, whereas LPS-
induced SOCS3 mRNA expression in RAW 264.7 mouse
macrophages was only partially attenuated. Thus, one may
conclude that the p38 MAP kinase plays an important role
in the inhibitory e¡ect of TNFK (or LPS) on IL-6 signaling.
4. Discussion
This study demonstrates that pre-treatment of di¡erent
types of macrophages with the pro-in£ammatory mediators
TNFK or LPS largely decreased or even completely abolished
STAT3 activation after IL-6-stimulation. This inhibition
closely correlates with the induction of SOCS3 mRNA by
LPS or TNFK. Since neither LPS nor TNFK in£uenced IL-
6-induced STAT3 activation in HepG2 cells or primary hep-
atocytes from rat liver, this e¡ect seems to be macrophage-
speci¢c.
Both, LPS and TNFK have shown to be potent activators
of the p38 MAP kinase as well as other members of the MAP
kinase family ([13,21,22], for review [23]). Using a speci¢c
inhibitor of the p38 MAP kinase, we obtained evidence that
p38 is involved, particularly in the inhibition of IL-6 signaling
by TNFK (Fig. 4). Most interestingly, inhibition of the p38
activity not only neutralized the TNFK e¡ect on IL-6-induced
STAT3 activation but also suppressed induction of SOCS3
mRNA by TFNK, suggesting that inhibition of STAT3 acti-
vation and induction of SOCS3 mRNA are functionally
linked. On the other hand our data indicate that p38 activa-
tion by LPS does only partially contribute to the inhibitory
in£uence of LPS on activation of STAT3 by IL-6. Accord-
ingly increased SOCS3 expression due to stimulation with
LPS was largely reduced after pre-treatment with SB202190
but was still comparable to that observed after treatment with
10 ng/ml TNFK. Therefore, besides p38 activation, additional
signaling events are required to explain the LPS-mediated in-
crease in SOCS3 mRNA levels and its suppressive action on
IL-6 signal transduction.
LPS has recently been described to induce expression of
SOCS3 but not SOCS1 or SOCS2 mRNA and protein in a
macrophage cell line. This was shown to correlate not only
with the inhibition of IFNQ-dependent long term activation of
Jak1 and STAT1 but also with the suppression of Jak2 and
STAT5 activation by granulocyte/macrophage-colony-stimu-
lating factor [24]. The authors also showed that inhibition
of IFNQ signaling does not occur until 4 h of LPS pre-incu-
bation. This was discussed to be a possible mechanism respon-
Fig. 3. E¡ect of LPS or TNFK on SOCS3 mRNA expression and on IL-6-induced STAT3 activation in human hepatoma cells (HepG2) and in
rat hepatocytes. HepG2 cells (a,c,e) and rat hepatocytes (b,d) were pre-treated with either TNFK or LPS and stimulated with IL-6 as indicated.
After the respective incubation period cells were harvested and nuclear extracts were prepared. EMSAs were performed as described in the
legend to Fig. 1. For (e) HepG2 cells were treated with IL-6, TNFK and LPS as indicated. Thereafter cells were harvested for the isolation of
total RNA, subsequently subjected to Northern blot analysis for SOCS3 and GAPDH as described in Section 2.
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sible for the LPS tolerance of macrophages after long term
exposure to endotoxins. In contrast, short term pre-treatment
with LPS even enhanced the transcriptional response to IFNQ
as well as STAT1 serine- and tyrosine-phosphorylation [3].
Our data show that LPS as well as TNFK inhibit IL-6-
induced STAT3 activation already after a pre-incubation pe-
riod of 30 min (Fig. 1), suggesting that early inhibition of IL-6
signaling can not be considered in the context of the emer-
gence of LPS tolerance in macrophages. With respect to this
observation it is important to note that IL-6 shows distinct
anti-in£ammatory properties. Thus, as an example IL-6 was
shown to inhibit the synthesis of TNFK and IL-1 both in vivo
and in vitro in response to several stimuli [25^27]. Moreover,
it was shown that IL-6 suppressed the macrophage-colony-
stimulating factor-induced proliferation and di¡erentiation
of both tissue and bone marrow macrophages [28]. It is at-
tractive to speculate that parts of the IL-6 signaling cascade
are inhibited after short term exposure of macrophages to the
pro-in£ammatory mediators LPS and TNFK in order to en-
force in£ammatory response to pathogens whereas at the
same time anti-in£ammatory properties of IL-6 are sup-
pressed. In such a scenario the early SOCS3 expression would
promote the activation of macrophages, whereas its long term
expression would lead to a desensitization towards other me-
diators like IFNQ. Further studies are needed to establish the
role and the pathophysiological implications of the inhibition
of IL-6 signaling by LPS or TNFK in macrophages.
Inhibition of IL-6 signaling by LPS or TNFK was not ob-
served in the human hepatoma cell line HepG2 and in pri-
mary hepatocytes from rat liver. The lack of the inhibitory
e¡ect of LPS on IL-6 signaling in HepG2 cells or hepatocytes
might be due to the absence of LPS binding protein, since this
protein was shown to be required for stimulation of HepG2
cells by LPS [29]. To our knowledge no di¡erences have been
described so far between HepG2/hepatocytes and macro-
phages in respect to the signal transduction of TNFK. How-
ever, the fact that TNFK is capable to induce SOCS3 mRNA
expression and inhibit STAT3 activation in macrophages but
not in HepG2 or hepatocytes suggests that the signaling of
TNFK is di¡erent in these two cell types.
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